Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
作者信息
Chow Victor A, Gopal Ajay K, Maloney David G, Turtle Cameron J, Smith Stephen D, Ujjani Chaitra S, Shadman Mazyar, Cassaday Ryan D, Till Brian G, Tseng Yolanda D, Warren Edus H, Shustov Andrei R, Menon Manoj P, Bhark Sandra, Acharya Utkarsh H, Mullane Erin, Hannan Lindsay M, Voutsinas Jenna M, Gooley Ted A, Lynch Ryan C
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Seattle Cancer Care Alliance, Seattle, Washington.
出版信息
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
Abstract
摘要
相似文献
1
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
2
Late Events After CD-19 CAR-T Treatment.
Biol Blood Marrow Transplant. 2020 Jan;26(1):e1-e2. doi: 10.1016/j.bbmt.2019.10.020. Epub 2019 Oct 25.
3
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
4
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z.
5
CAR T cell therapy for B-cell lymphomas.
Best Pract Res Clin Haematol. 2018 Jun;31(2):135-146. doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11.
6
Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918. doi: 10.1007/s00432-018-2818-y. Epub 2018 Dec 11.
7
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
Leuk Lymphoma. 2024 Jun;65(6):868-871. doi: 10.1080/10428194.2024.2325188. Epub 2024 Mar 5.
8
CAR T-cell therapy in refractory large B-cell lymphoma.
Lancet Oncol. 2018 Jan;19(1):e19. doi: 10.1016/S1470-2045(17)30928-2. Epub 2017 Dec 14.
9
[CAR-T cells in lymphomas: Current and evolving role].
Bull Cancer. 2021 Oct;108(10S):S28-S39. doi: 10.1016/j.bulcan.2021.04.022.
10
Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
Exp Hematol. 2018 Oct;66:5-16. doi: 10.1016/j.exphem.2018.07.002. Epub 2018 Jul 20.
引用本文的文献
1
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.
J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.
2
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.
Cell Transplant. 2025 Jan-Dec;34:9636897251338713. doi: 10.1177/09636897251338713. Epub 2025 Jun 5.
3
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.
Blood Adv. 2025 Aug 12;9(15):3955-3966. doi: 10.1182/bloodadvances.2024015719.
4
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL.
Cancer Immunol Immunother. 2025 Mar 22;74(5):156. doi: 10.1007/s00262-025-04001-7.
5
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044.
6
Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming.
J Immunother Cancer. 2024 Nov 17;12(11):e009949. doi: 10.1136/jitc-2024-009949.
7
Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Cancer Med. 2024 Sep;13(17):e70138. doi: 10.1002/cam4.70138.
8
The basic biology of NK cells and its application in tumor immunotherapy.
Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024.
9
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.
Blood Adv. 2024 Sep 24;8(18):4877-4885. doi: 10.1182/bloodadvances.2024013647.
10
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.
Front Oncol. 2024 Jun 25;14:1376490. doi: 10.3389/fonc.2024.1376490. eCollection 2024.
本文引用的文献
1
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
2
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
3
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
4
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
5
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
Bone Marrow Transplant. 2017 Feb;52(2):216-221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19.
6
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
Zotero 插件